… The development and introduction of sugammadex (… sugammadex with or without the prior
administration of rocuronium [12]. This study showed that the administration of sugammadex …

… Sugammadex and the sugammadex-rocuronium complex do not bind to plasma proteins
or erythrocytes. Sugammadex … Administration of sugammadex following that of rocuronium …

… Intravenous sugammadex was generally well tolerated. In conclusion, sugammadex is an
… proteins or erythrocytes and sugammadex or the sugammadex-rocuronium complex [6, 25]. …

… Sugammadex will also facilitate the use of rocuronium for … The clinical use of sugammadex
promises to eliminate many of the … unique characteristics of sugammadex and describes how …

… Sugammadex volume of distribution is … Sugammadex and the sugammadex-rocuronium
complex do not bind to plasma proteins. The mean plasma clearance of sugammadex is 0.084 …

… is the encapsulating agent sugammadex. This agent has … This review describes the effects
of sugammadex in in vitro … blockade because the dose of sugammadex can be adjusted to …

… Sugammadex is a cyclodextrin molecule that encapsulates … sugammadex is optimised for
reversing rocuronium it is most likely to be used in conjunction with this drug. Sugammadex will …

… Sugammadex is a drug … to sugammadex. A comprehensive search was performed in PubMed,
Scopus and Web of Science for cases reporting hypersensitivity reactions to sugammadex…

… potential of reverse of their action with sugammadex, seems to be safe in patients … sugammadex
is not yet available. Evidence suggesting an economic advantage of using sugammadex …

… sugammadex to be safe and effective. Further studies followed, resulting in sugammadex …
These issues have yet to be resolved with sugammadex still being unavailable in the United …